REVENUE (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The Company's revenue by segment payers/customer groups for the years ended December 31, 2022, 2021 and 2020 is as follows:

	For the Year Ended December 31, 2022								For the Year Ended December 31, 2021								For the Year Ended December 31, 2020
	North America		Europe		Other		Total		North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	18	%	—	%	—	%	18	%	17	%	—	%	—	%	17	%	20	%	—	%	—	%	20	%
Patients	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%	6	%	—	%	—	%	6	%
Medicare and Medicaid	6	%	—	%	—	%	6	%	7	%	—	%	—	%	7	%	7	%	—	%	—	%	7	%
Third party	31	%	—	%	—	%	31	%	34	%	—	%	—	%	34	%	32	%	—	%	—	%	32	%
Total Dx revenues by payer	61	%	—	%	—	%	61	%	64	%	—	%	—	%	64	%	65	%	—	%	—	%	65	%
DD
Pharmaceutical, biotechnology and medical device companies	19	%	13	%	7	%	39	%	17	%	13	%	6	%	36	%	17	%	11	%	7	%	35	%
Total revenues	80	%	13	%	7	%	100	%	81	%	13	%	6	%	100	%	82	%	11	%	7	%	100	%

Capitalized Contract Cost

	December 31, 2022		December 31, 2021
Sales commission assets	$	38.2	$	36.2
Deferred contract fulfillment costs	15.0		14.4
Total	$	53.2	$	50.6

Contract with Customer, Contract Asset, Contract Liability, and Receivable

	December 31, 2022		December 31, 2021
Dx accounts receivable	$	1,046.9	$	1,193.8
DD accounts receivable	1,218.6		1,089.2
Less DD allowance for doubtful accounts	(43.5)		(21.5)
Accounts receivable	$	2,222.0	$	2,261.5
Gross unbilled services	$	805.9	$	730.8
Less reserve for unbilled services	(10.5)		(14.0)
Unbilled services	$	795.4	$	716.8
Unearned revenue	$	582.1	$	558.5